网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
基于加权基因共表达网络分析的BRAF突变分化型甲状腺癌预后标志物筛选
作者:牛亦奇  邓先兆  郭伯敏  康杰  伍波  樊友本 
单位:上海交通大学附属第六人民医院 普外科, 上海 200233
关键词:分化型甲状腺癌 BRAF基因突变 加权基因共表达网络分析 预后标志物 
分类号:R653
出版年·卷·期(页码):2020·48·第十一期(1385-1395)
摘要:

目的:构建鼠类肉瘤滤过性病毒致癌同源体B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF)基因突变分化型甲状腺癌的基因共表达网络并筛选预后标志物,加强此类患者的术前风险评估。方法:从肿瘤基因组图谱数据库下载甲状腺癌与癌旁组织样本的基因转录组表达数据及临床资料。用加权基因共表达网络分析来构建BRAF基因突变调控的基因共表达模块,通过模块的表型相关性分析找到有临床意义的模块,并在模块中筛选BRAF基因突变的分化型甲状腺癌特异性的预后标志物。结果:成功构建3个分化型甲状腺癌中BRAF基因突变调控的基因共表达模块,其中2个模块与颈部淋巴结转移分期相关。在这两个模块中找到与分化型甲状腺癌预后相关的基因有9个:SLC26A4、SOD3、KIT、GNAI1、FN1、ITGA2、IQGAP2、SORBS2和ITGA3;且FN1和ITGA3的高表达与BRAF基因突变分化型甲状腺癌患者无病生存期缩短有关。结论:建立分化型甲状腺癌中BRAF基因突变调控的基因共表达模块与颈部淋巴结转移分期之间的联系,筛选出FN1和ITGA3是BRAF基因突变的分化型甲状腺癌的特异性预后标志物。

参考文献:

[1] LA VECCHIA C,MALVEZZI M,BOSETTI C,et al.Thyroid cancer mortality and incidence:a global overview[J].Int J Cancer,2015,136(9):2187-2195.
[2] LIM H,DEVESA S S,SOSA J A,et al.Trends in Thyroid Cancer Incidence and Mortality in the United States,1974-2013[J].JAMA,2017,317(13):1338-1348.
[3] XIANG J,WU Y,LI D S,et al.New clinical features of thyroid cancer in eastern China[J].J Visc Surg,2010,147(1):e53-56.
[4] TUTTLE R M,BALL D W,BYRD D,et al.Thyroid carcinoma[J].J Natl Compr Canc Netw,2010,8(11):1228-1274.
[5] MCLEOD D S.Current concepts and future directions in differentiated thyroid cancer[J].Clin Biochem Rev,2010,31(1):9-19.
[6] NIKIFOROV Y E,NIKIFOROVA M N.Molecular genetics and diagnosis of thyroid cancer[J].Nat Rev Endocrinol,2011,7(10):569-580.
[7] KIMURA E T,NIKIFOROVA M N,ZHU Z,et al.High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J].Cancer Res,2003,63(7):1454-1457.
[8] XING M,WESTRA W H,TUFANO R P,et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J].J Clin Endocrinol Metab,2005,90(12):6373-6379.
[9] XING M.BRAF mutation in papillary thyroid cancer:pathogenic role,molecular bases,and clinical implications[J].Endocr Rev,2007,28(7):742-762.
[10] XING M,ALZAHRANI A S,CARSON K A,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].Jama,2013,309(14):1493-1501.
[11] XING M,ALZAHRANI A S,CARSON K A,et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J].J Clin Oncol,2015,33(1):42-50.
[12] SONG Y S,LIM J A,PARK Y J.Mutation Profile of Well-Differentiated Thyroid Cancer in Asians[J].Endocrinol Metab (Seoul),2015,30(3):252-262.
[13] TAVAZOIE S,HUGHES J D,CAMPBELL M J,et al.Systematic determination of genetic network architecture[J].Nat Genet,1999,22(3):281-285.
[14] FUGAZZOLA L,MANNAVOLA D,CIRELLO V,et al.BRAF mutations in an Italian cohort of thyroid cancers[J].Clin Endocrinol (Oxf),2004,61(2):239-243.
[15] BRZEZIANSKA E,PASTUSZAK-LEWANDOSKA D,WOJCIECHOWSKA K,et al.Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population[J].Neuro Endocrinol Lett,2007,28(4):351-359.
[16] KIM T Y,KIM W B,SONG J Y,et al.The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma[J].Clin Endocrinol (Oxf),2005,63(5):588-593.
[17] SOHN S Y,PARK W Y,SHIN H T,et al.Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer[J].Thyroid,2016,26(5):672-682.
[18] SHEN X,LIU R,XING M.A six-genotype genetic prognostic model for papillary thyroid cancer[J].Endocr Relat Cancer,2017,24(1):41-52.
[19] SONG Y S,LIM J A,CHOI H,et al.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients[J].Cancer,2016,122(9):1370-1379.
[20] XING M.Genetic-guided Risk Assessment and Management of Thyroid Cancer[J].Endocrinol Metab Clin North Am,2019,48(1):109-124.
[21] TOMCZAK K,CZERWINSKA P,WIZNEROWICZ M.The Cancer Genome Atlas (TCGA):an immeasurable source of knowledge[J].Contemp Oncol (Pozn),2015,19(1A):A68-77.
[22] ZHANG B,HORVATH S.A general framework for weighted gene co-expression network analysis[J].Stat Appl Genet Mol Biol,2005,4:Article17.
[23] HORVATH S,DONG J.Geometric interpretation of gene coexpression network analysis[J].PLoS Comput Biol,2008,4(8):e1000117.
[24] LANGFELDER P,HORVATH S.WGCNA:an R package for weighted correlation network analysis[J].BMC Bioinformatics,2008,9:559.
[25] CARTER S L,BRECHBUHLER C M,GRIFFIN M,et al.Gene co-expression network topology provides a framework for molecular characterization of cellular state[J].Bioinformatics,2004,20(14):2242-2250.
[26] SZKLARCZYK D,MORRIS J H,COOK H,et al.The STRING database in 2017:quality-controlled protein-protein association networks,made broadly accessible[J].Nucleic Acids Res,2017,45(D1):D362- D368.
[27] TANG Z,LI C,KANG B,et al.GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[28] 肖婧,杨昱.甲状腺乳头状癌患者的预后及相关因素分析[J].中国卫生统计,2019,36(5):740-742.
[29] 吴延升,张仑,王旭东,等.甲状腺乳头状癌预后多因素分析[J].中国肿瘤临床,2007(22):1294-1297.
[30] 顾耀耀,倪雪君.超声在甲状腺癌颈部淋巴结转移临床诊断中的实用价值[J].诊断学理论与实践,2019,18(06):662-667.
[31] LLAMAS-OLIER A E,CUELLAR D I,BUITRAGO G.Intermediate-Risk Papillary Thyroid Cancer:Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy[J].Thyroid,2018,28(10):1311-1317.
[32] LUO X,WU A.Analysis of risk factors for postoperative recurrence of thyroid cancer[J].J Buon,2019,24(2):813-818.
[33] ZHAO L,WANG W,HUANG S,et al.The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts[J].Genome Biol,2018,19(1):35.
[34] HAN L,HUANG C,ZHANG S.The RNA-binding protein SORBS2 suppresses hepatocellular carcinoma tumourigenesis and metastasis by stabilizing RORA mRNA[J].Liver Int,2019,39(11):2190-2203.
[35] YAN B,PENG Z,XING C.SORBS2,mediated by MEF2D,suppresses the metastasis of human hepatocellular carcinoma by inhibitiing the c-Abl-ERK signaling pathway[J].Am J Cancer Res,2019,9(12):2706-2718.
[36] VAITHEESVARAN B,HARTIL K,NAVARE A,et al.Role of the tumor suppressor IQGAP2 in metabolic homeostasis:Possible link between diabetes and cancer[J].Metabolomics,2014,10(5):920-937.
[37] LIANG H,YU M,YANG R,et al.A PTAL-miR-101-FN1 Axis Promotes EMT and Invasion-Metastasis in Serous Ovarian Cancer[J].Mol Ther Oncolytics,2020,16:53-62.
[38] ZHAN S,LI J,WANG T,et al.Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker[J].Oncologist,2018,23(12):1415-1425.
[39] JIAO Y,LI Y,LIU S,et al.ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer[J].Onco Targets Ther,2019,12:4141-4152.
[40] WANG J R,LIU B,ZHOU L,et al.MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer[J].Cancer Biomark,2019,24(2):159-172.
[41] BIJNSDORP I V,GELDOF A A,LAVAEI M,et al.Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients[J].J Extracell Vesicles,2013,2.
[42] LIU H,CHEN X,LIN T,et al.MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways[J].J Cell Physiol,2019,234(10):18382-18391.
[43] CHERNAYA G,MIKHNO N,KHABALOVA T,et al.The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation[J].Surg Oncol,2018,27(4):702-708.
[44] LI Z W,SUN B,GONG T,et al.GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Down-regulating Expression of GNAI2[J].Gastroenterology,2019,156(8):2297-2312.
[45] YAO J,LIANG L H,ZHANG Y,et al.GNAI1 Suppresses Tumor Cell Migration and Invasion and is Post-Transcriptionally Regulated by Mir-320a/c/d in Hepatocellular Carcinoma[J].Cancer Biol Med,2012,9(4):234-241.
[46] NIKIFOROV Y E.Role of Molecular Markers in Thyroid Nodule Management:Then and Now[J].Endocr Pract,2017,23(8):979-988.
[47] LIU R,BISHOP J,ZHU G,et al.Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer:Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality[J].JAMA Oncol,2017,3(2):202-208.
[48] MOON S,SONG Y S,KIM Y A,et al.Effects of Coexistent BRAF(V600E) and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer:A Meta-Analysis[J].Thyroid,2017,27(5):651-660.
[49] ZHENG B,LIU J,GU J,et al.A three-gene panel that distinguishes benign from malignant thyroid nodules[J].Int J Cancer,2015,136(7):1646-1654.
[50] NICHOLSON K J,YIP L.An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer[J].Curr Opin Oncol,2018,30(1):8-15.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 437121 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541